Fujioka et al. (43) were the first to propose that a preferential accumulation of intra-abdominal adipose tissue could explain the deterioration in glucose and lipid metabolism observed in obese patients. In their study, subjects with a preferential accumulation of intra-abdominal adipose tissue had higher fasting plasma triglyceride levels and higher plasma glucose responses following an oral glucose tolerance test (OGTT) than subjects with the same BMI values but a preferential accumulation of abdominal subcutaneous adipose tissue. The independent contribution of intra-abdominal adipose tissue vs. subcutaneous adipose tissue has also been examined in obese individuals with similar BMI values but either low or high amounts of intra-abdominal adipose tissue (48, 49). While obese subjects with low levels of intra-abdominal adipose tissue had a basically normal plasma lipoprotein-lipid profile, the subgroup of obese individuals with elevated intra-abdominal fat had the worst metabolic profile: fasting hypertriglyceridemia, low HDL cholesterol concentrations, glucose intolerance, hyperinsulinemia, and a prothrombotic and inflammatory state. Additional studies by Ross et al. (50, 51) further explored the relationship between intra-abdominal adipose tissue and metabolic risk in men and women. When individuals who were matched for similar abdominal subcutaneous adipose tissue but had different levels of intra-abdominal adipose tissue were compared, it was revealed that subjects with high intra-abdominal adipose tissue had higher glucose values following an OGTT and lower glucose disposal values compared to subjects with low intra-abdominal adipose tissue. This means that obese individuals with a preferential accumulation of intra-abdominal adipose tissue may form an obese subgroup at highest risk of CVD. These findings indicate that overall obesity is associated with moderate metabolic complications, but that excess intra-abdominal adipose tissue is associated with a cluster of metabolic abnormalities that increase CVD risk. Therefore, for the same amount of total body fat, individuals with more intra-abdominal adipose tissue are at significantly greater risk of also having features of the metabolic syndrome (48-52).

Role of the Dysregulated Endocannabinoid System in Determining Cardiometabolic Risk by Vincenzo Di Marzo, PhD
More
What is the role of low HDL cholesterol in the elevated CHD risk of metabolic syndrome patients? By Philip J. Barter, MBBS, FRACP, PhD
More
Hypertrophy and hyperplasia of abdominal adipose tissues in women. Int J Obes (Lond) 2008;32:283-91
More
Schematic representation of how smoking might add to several mechanisms linking obesity to cardiovascular disease
More